BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 25033218)

  • 1. In vitro and in vivo miltefosine susceptibility of a Leishmania amazonensis isolate from a patient with diffuse cutaneous leishmaniasis.
    Coelho AC; Trinconi CT; Costa CH; Uliana SR
    PLoS Negl Trop Dis; 2014 Jul; 8(7):e2999. PubMed ID: 25033218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amphotericin B resistance in Leishmania amazonensis: In vitro and in vivo characterization of a Brazilian clinical isolate.
    Ferreira BA; Coser EM; de la Roca S; Aoki JI; Branco N; Soares GHC; Lima MIS; Coelho AC
    PLoS Negl Trop Dis; 2024 May; 18(5):e0012175. PubMed ID: 38768213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In Vitro and In Vivo Miltefosine Susceptibility of a Leishmania amazonensis Isolate from a Patient with Diffuse Cutaneous Leishmaniasis: Follow-Up.
    Coelho AC; Trinconi CT; Costa CH; Uliana SR
    PLoS Negl Trop Dis; 2016 Jul; 10(7):e0004720. PubMed ID: 27416021
    [No Abstract]   [Full Text] [Related]  

  • 4. The antifungal compound butenafine eliminates promastigote and amastigote forms of Leishmania (Leishmania) amazonensis and Leishmania (Viannia) braziliensis.
    Bezerra-Souza A; Yamamoto ES; Laurenti MD; Ribeiro SP; Passero LF
    Parasitol Int; 2016 Dec; 65(6 Pt A):702-707. PubMed ID: 27546158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of tamoxifen and miltefosine combined therapy for cutaneous leishmaniasis in the murine model of infection with Leishmania amazonensis.
    Trinconi CT; Reimão JQ; Coelho AC; Uliana SR
    J Antimicrob Chemother; 2016 May; 71(5):1314-22. PubMed ID: 26851606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reductions in skin and systemic parasite burdens as a combined effect of topical paromomycin and oral miltefosine treatment of mice experimentally infected with Leishmania (Leishmania) amazonensis.
    Aguiar MG; Pereira AM; Fernandes AP; Ferreira LA
    Antimicrob Agents Chemother; 2010 Nov; 54(11):4699-704. PubMed ID: 20713665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of paromomycin against Leishmania amazonensis: Direct correlation between susceptibility in vitro and the treatment outcome in vivo.
    Coser EM; Ferreira BA; Branco N; Yamashiro-Kanashiro EH; Lindoso JAL; Coelho AC
    Int J Parasitol Drugs Drug Resist; 2020 Dec; 14():91-98. PubMed ID: 33011651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of miltefosine treatment in Leishmania amazonensis-infected BALB/c mice.
    Godinho JL; Simas-Rodrigues C; Silva R; Ürmenyi TP; de Souza W; Rodrigues JC
    Int J Antimicrob Agents; 2012 Apr; 39(4):326-31. PubMed ID: 22226653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment failure and miltefosine susceptibility in dermal leishmaniasis caused by Leishmania subgenus Viannia species.
    Obonaga R; Fernández OL; Valderrama L; Rubiano LC; Castro Mdel M; Barrera MC; Gomez MA; Gore Saravia N
    Antimicrob Agents Chemother; 2014; 58(1):144-52. PubMed ID: 24145529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo.
    Seifert K; Pérez-Victoria FJ; Stettler M; Sánchez-Cañete MP; Castanys S; Gamarro F; Croft SL
    Int J Antimicrob Agents; 2007 Sep; 30(3):229-35. PubMed ID: 17628445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Miltefosine-resistant Leishmania infantum strains with an impaired MT/ROS3 transporter complex retain amphotericin B susceptibility.
    Mondelaers A; Hendrickx S; Van Bockstal L; Maes L; Caljon G
    J Antimicrob Chemother; 2018 Feb; 73(2):392-394. PubMed ID: 29165590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Semicarbazone derivatives as promising therapeutic alternatives in leishmaniasis.
    Cavalcanti de Queiroz A; Alves MA; Barreiro EJ; Lima LM; Alexandre-Moreira MS
    Exp Parasitol; 2019 Jun; 201():57-66. PubMed ID: 31004571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Case report: Transient success using prolonged treatment with miltefosine for a patient with diffuse cutaneous leishmaniasis infected with Leishmania mexicana mexicana.
    Ordaz-Farias A; Muñoz-Garza FZ; Sevilla-Gonzalez FK; Arana-Guajardo A; Ocampo-Candiani J; Treviño-Garza N; Becker I; Camacho-Ortiz A
    Am J Trop Med Hyg; 2013 Jan; 88(1):153-6. PubMed ID: 23243111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Laboratory confirmed miltefosine resistant cases of visceral leishmaniasis from India.
    Srivastava S; Mishra J; Gupta AK; Singh A; Shankar P; Singh S
    Parasit Vectors; 2017 Jan; 10(1):49. PubMed ID: 28137296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Luciferase-Expressing Leishmania braziliensis Line That Leads to Sustained Skin Lesions in BALB/c Mice and Allows Monitoring of Miltefosine Treatment Outcome.
    Coelho AC; Oliveira JC; Espada CR; Reimão JQ; Trinconi CT; Uliana SR
    PLoS Negl Trop Dis; 2016 May; 10(5):e0004660. PubMed ID: 27144739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel organic salts based on quinoline derivatives: The in vitro activity trigger apoptosis inhibiting autophagy in Leishmania spp.
    Calixto SL; Glanzmann N; Xavier Silveira MM; da Trindade Granato J; Gorza Scopel KK; Torres de Aguiar T; DaMatta RA; Macedo GC; da Silva AD; Coimbra ES
    Chem Biol Interact; 2018 Sep; 293():141-151. PubMed ID: 30098941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leishmania is not prone to develop resistance to tamoxifen.
    Coelho AC; Trinconi CT; Senra L; Yokoyama-Yasunaka JK; Uliana SR
    Int J Parasitol Drugs Drug Resist; 2015 Dec; 5(3):77-83. PubMed ID: 26150922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The in vitro leishmanicidal activity of hexadecylphosphocholine (miltefosine) against four medically relevant Leishmania species of Brazil.
    Morais-Teixeira Ed; Damasceno QS; Galuppo MK; Romanha AJ; Rabello A
    Mem Inst Oswaldo Cruz; 2011 Jun; 106(4):475-8. PubMed ID: 21739037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence of a drug-specific impact of experimentally selected paromomycin and miltefosine resistance on parasite fitness in Leishmania infantum.
    Hendrickx S; Beyers J; Mondelaers A; Eberhardt E; Lachaud L; Delputte P; Cos P; Maes L
    J Antimicrob Chemother; 2016 Jul; 71(7):1914-21. PubMed ID: 27084919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation of luciferase-expressing Leishmania infantum chagasi and assessment of miltefosine efficacy in infected hamsters through bioimaging.
    Reimão JQ; Oliveira JC; Trinconi CT; Cotrim PC; Coelho AC; Uliana SR
    PLoS Negl Trop Dis; 2015 Feb; 9(2):e0003556. PubMed ID: 25679212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.